Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2023-05-08

FDA Approved: BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE — Supplemental Application (PAI Holdings, LLC dba PAI Pharma)

View source ↗

Summary

FDA approved a supplemental application for the cough/cold combination of brompheniramine maleate, pseudoephedrine hydrochloride, and dextromethorphan hydrobrom…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Brompheniramine maleate, pseudoephedrine hydrochloride and dextromethorphan hydrobromide (brompheniramine maleate; pseudoephedrine hydrochloride; dextromethorphan hydrobromide)

Snippet

SUPPL AP for BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE (BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE, AND DEXTROMETHORPHAN HYDROBROMIDE)